Biopharma Daily Stock Updates - 04/08/21

$IBRX -1% Preliminary Phase 1b data reported. source

$MRNA +2% Publication of antibody persistence data out to 6 months following the second dose. source

$ATOS -5% Expanded access treatment underway. source

$PRVB -41% FDA noted additional data would be required for BLA. source

$APRE +15% Eprenetapopt granted Orphan Drug Designation. source

$AUPH +2% Additional data from pivotal trial presented at SCM21. source

$RNLX +5% Presented data at SCM21. source

$GILD -1% FDA approval to Trodelvy®. source

$KMPH -1% Amendment to the definitive collaboration and license agreement with GPC. source

$GLPG +1% Amendment to the share subscription agreement closed in 2019 with $GILD. source

$JAGX +3% Update to equity purchase agreement. source

$DRNA +3% Sold royalty rights for OXLUMO to $RPRX. source